Our Services
Medical Information
Helpful Resources
Published on: 3/18/2026
If your ulcerative colitis (UC) is still flaring despite treatment, several factors may be responsible: poor medication fit, secondary loss of response, persistent inflammation, or non-UC causes such as infection or IBS overlap. Next steps typically involve objective reassessment—optimizing current therapy or switching drug classes. Options may include oral JAK inhibitors for UC like tofacitinib or upadacitinib, which require appropriate screening and monitoring.
Key safety considerations, red flag symptoms, guidance on tests, drug levels, clinical trials, and when surgery is appropriate are detailed below, all of which can significantly influence the best path forward with your care team.
Because ongoing UC flares can signal anything from a simple treatment adjustment to a more serious underlying issue, it's important to clarify what your symptoms may mean before your next appointment. Take a free, instant, online symptom check to better understand what's going on and confidently navigate your next steps.
Reviewed for medical accuracy: 07/09/2026
If you're living with ulcerative colitis (UC) and still flaring despite treatment, you're not alone. Many people with UC go through periods where medications seem to lose effectiveness or never fully control symptoms in the first place.
Ongoing diarrhea, urgency, blood in the stool, abdominal pain, and fatigue can be frustrating and exhausting. The good news is that treatment options have expanded significantly in recent years — including newer JAK inhibitors for UC, which may offer another path forward when other medications haven't worked.
Let's break down why your gut may be "resisting" treatment and what your next steps could be.
There are several medically recognized reasons UC symptoms can persist despite treatment.
Ulcerative colitis is not a one-size-fits-all disease. It varies in:
Common UC treatments include:
If inflammation remains active, it may mean your current medication isn't strong enough — or isn't targeting the right inflammatory pathway.
Even if a medication worked before, it may stop working. This is called secondary loss of response.
This can happen because:
In these cases, your doctor may:
Symptoms can come and go, but inflammation may still be damaging your colon lining. Ongoing inflammation increases the risk of:
This is why doctors aim for more than symptom relief — they aim for mucosal healing (healing of the colon lining seen on colonoscopy).
Sometimes worsening symptoms are caused by:
That's why reassessment is important if symptoms change.
If you're experiencing new or worsening symptoms and want to better understand what might be going on, you can use a free AI-powered tool to check your Ulcerative Colitis symptoms and get personalized insights before your next doctor's appointment.
If you've failed or lost response to conventional therapies or biologics, your doctor may discuss JAK inhibitors for UC as a next step.
JAK inhibitors (Janus kinase inhibitors) are oral medications that block specific enzymes inside immune cells. These enzymes are part of the signaling system that drives inflammation in ulcerative colitis.
Instead of targeting a single inflammatory molecule (like some biologics do), JAK inhibitors work inside the immune cell, interrupting multiple inflammatory signals at once.
Currently approved JAK inhibitors for UC include:
These medications are supported by large clinical trials and are approved for moderate to severe ulcerative colitis.
Clinical studies show that JAK inhibitors can:
They are particularly useful for people who:
For many patients, the speed of symptom relief is one of the most meaningful benefits.
Like all immune-modifying medications, JAK inhibitors for UC carry potential risks. It's important to be informed — not alarmed.
Possible risks include:
Because of these risks, doctors:
For many patients, the benefits outweigh the risks — especially when UC remains uncontrolled. The key is individualized decision-making with your gastroenterologist.
If symptoms persist, your doctor may recommend:
Moving from:
There are ongoing studies investigating new oral agents and biologics.
In severe, treatment-resistant cases, surgery to remove the colon may be recommended. While this can sound overwhelming, it can also be life-changing for patients with uncontrolled disease.
While most flares are manageable, seek urgent medical care if you experience:
These situations can be serious or life-threatening. Speak to a doctor immediately if any of these occur.
It's important to be realistic.
Not every medication works for every person. Finding the right therapy can take time. But the treatment landscape for ulcerative colitis has improved dramatically in the last decade.
JAK inhibitors for UC represent a major advance, especially for patients who previously had limited options after biologic failure.
The goal today is not just symptom control — it's sustained remission and prevention of long-term damage.
If you're still flaring:
If you're unsure whether what you're experiencing is an active flare or something else entirely, consider checking your Ulcerative Colitis symptoms with a free online assessment tool to help you prepare for a more informed conversation with your gastroenterologist.
Persistent flares don't mean you've failed. And they don't mean your condition is hopeless.
They usually mean your treatment plan needs adjusting.
With modern therapies — including JAK inhibitors for UC — many patients who once struggled to find relief are now achieving remission.
But ulcerative colitis is a serious inflammatory disease. Never ignore severe symptoms, and always speak to a doctor about anything that could be life-threatening or worsening.
The right treatment may not be the first one you try — but it may be the next one.
(References)
* Al-Sadi, H., & Al-Zoubi, M. M. (2022). Management of Refractory Ulcerative Colitis: A Comprehensive Review. Inflammatory Bowel Diseases, 28(10), 1546-1558.
* Danese, S., & Peyrin-Biroulet, L. (2022). Optimizing the use of JAK inhibitors in ulcerative colitis. Lancet Gastroenterology & Hepatology, 7(12), 1163-1175.
* Sandborn, W. J., & Feagan, B. G. (2023). Advances in the management of ulcerative colitis: Current and emerging therapies. Lancet Gastroenterology & Hepatology, 8(1), 77-89.
* Ungaro, R., & Colombel, J. F. (2020). Mechanisms of resistance to biologic therapies in inflammatory bowel disease. Gastroenterology, 159(3), 774-789.
* Regueiro, M., & Dulai, P. S. (2023). Stratifying Patients With Ulcerative Colitis to Optimize Treatment Response: Personalized Medicine in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 21(1), 22-30.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.